• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?

作者信息

Bullock Roger, Connolly Claire

机构信息

Kingshill Research Centre, Victoria Hospital, Okus Road, Swindon SN1 4HZ, UK.

出版信息

Int J Geriatr Psychiatry. 2002 Mar;17(3):288-9. doi: 10.1002/gps.542.

DOI:10.1002/gps.542
PMID:11921158
Abstract
摘要

相似文献

1
Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?阿尔茨海默病中胆碱酯酶抑制剂治疗的转换——从多奈哌齐换成卡巴拉汀，是否值得？
Int J Geriatr Psychiatry. 2002 Mar;17(3):288-9. doi: 10.1002/gps.542.
2
Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.阿尔茨海默病的非认知症状及长期治疗期望
Alzheimer Dis Assoc Disord. 2004 Apr-Jun;18 Suppl 1:S9-16. doi: 10.1097/01.wad.0000127494.03150.f8.
3
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.卡巴拉汀对使用多奈哌齐治疗无效的阿尔茨海默病患者的疗效和安全性。
Curr Med Res Opin. 2002;18(3):129-38. doi: 10.1185/030079902125000471.
4
Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.多奈哌齐和卡巴拉汀治疗阿尔茨海默病：已发表的关于其疗效和成本效益数据的最佳证据综合分析
Clin Ther. 2002 Jun;24(6):862-86; discussion 837. doi: 10.1016/s0149-2918(02)80004-2.
5
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.胆碱酯酶抑制剂对阿尔茨海默病痴呆的行为和心理症状管理有效吗？对多奈哌齐、卡巴拉汀和加兰他敏随机、安慰剂对照试验的系统评价。
Int Psychogeriatr. 2009 Oct;21(5):813-24. doi: 10.1017/S1041610209990354. Epub 2009 Jun 19.
6
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.阿尔茨海默病持续成功治疗的策略：更换胆碱酯酶抑制剂。
Curr Med Res Opin. 2003;19(8):707-14. doi: 10.1185/030079903125002450.
7
Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?阿尔茨海默病中的胆碱酯酶抑制剂：多奈哌齐还是卡巴拉汀？
Int J Clin Pract. 2002 Jul-Aug;56(6):414-5.
8
Maintaining functional and behavioral abilities in Alzheimer disease.维持阿尔茨海默病患者的功能和行为能力。
Alzheimer Dis Assoc Disord. 2001 Aug;15 Suppl 1:S34-40. doi: 10.1097/00002093-200108001-00006.
9
Featured CME topic: dementia. Medication update.重点继续医学教育主题：痴呆症。药物更新。
South Med J. 2001 Jul;94(7):678-81.
10
Pharmacologic management of Alzheimer disease.阿尔茨海默病的药物治疗
J Neurosci Nurs. 2008 Feb;40(1):55-9. doi: 10.1097/01376517-200802000-00009.

引用本文的文献

1
Rapid neurobehavioural analysis based on the effects of an acetylcholinesterase inhibitor from Tephrosia purpurea in Zebrafish.基于紫穗槐中一种乙酰胆碱酯酶抑制剂对斑马鱼影响的快速神经行为分析。
Ann Neurosci. 2012 Jan;19(1):8-13. doi: 10.5214/ans.0972.7531.180403.
2
Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.接受胆碱酯酶抑制剂转换治疗的轻至中度阿尔茨海默病患者的认知和情感变化：一项为期6个月的观察性研究。
PLoS One. 2014 Feb 19;9(2):e89216. doi: 10.1371/journal.pone.0089216. eCollection 2014.
3
Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease.
在可能患有阿尔茨海默病的患者中，从口服胆碱酯酶抑制剂转换为利斯的明透皮贴剂的疗效和安全性。
J Clin Neurol. 2011 Sep;7(3):137-42. doi: 10.3988/jcn.2011.7.3.137. Epub 2011 Sep 29.
4
Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.从口服胆碱酯酶抑制剂转换为利斯的明透皮贴剂。
CNS Neurosci Ther. 2010 Spring;16(1):51-60. doi: 10.1111/j.1755-5949.2009.00119.x.
5
Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.某州医疗补助计划中乙酰胆碱酯酶抑制剂持续治疗率的比较
Patient Prefer Adherence. 2008 Feb 2;2:79-85. doi: 10.2147/ppa.s2652.
6
Progress update: Pharmacological treatment of Alzheimer's disease.进展更新：阿尔茨海默病的药物治疗。
Neuropsychiatr Dis Treat. 2007;3(5):569-78.
7
Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study.从多奈哌齐转换而来的卡巴拉汀在阿尔茨海默病患者中的长期安全性和耐受性：一项开放标签扩展研究。
Prim Care Companion J Clin Psychiatry. 2008;10(5):363-7. doi: 10.4088/pcc.v10n0503.
8
Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study.卡巴拉汀对多奈哌齐反应欠佳的阿尔茨海默病患者的安全性及有效性：一项开放标签研究
Prim Care Companion J Clin Psychiatry. 2008;10(4):291-8. doi: 10.4088/pcc.v10n0404.
9
Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: a starting point to explore Bayesian approximation in clinical practice.短期反应可预测阿尔茨海默病患者对乙酰胆碱酯酶抑制剂的长期反应：探索临床实践中贝叶斯近似法的起点
Bioinformation. 2007 Aug 16;2(2):43-9. doi: 10.6026/97320630002039.
10
Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.两种胆碱酯酶抑制剂的药物持续作用：卡巴拉汀与多奈哌齐在老年阿尔茨海默病患者中的比较
Drugs Aging. 2005;22(8):695-707. doi: 10.2165/00002512-200522080-00006.